Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $42.33.

A number of analysts recently issued reports on the company. HC Wainwright lowered their target price on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Piper Sandler reduced their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Scotiabank reduced their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Finally, Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock worth $30,981,000 after purchasing an additional 100,691 shares during the last quarter. Alkeon Capital Management LLC grew its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Braidwell LP grew its stake in shares of Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the last quarter. Finally, Darwin Global Management Ltd. grew its stake in shares of Keros Therapeutics by 10.7% in the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock worth $26,707,000 after purchasing an additional 163,403 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Trading Up 0.7 %

Shares of Keros Therapeutics stock opened at $11.67 on Monday. The company has a market capitalization of $473.36 million, a PE ratio of -2.24 and a beta of 1.39. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $72.37. The stock’s fifty day simple moving average is $12.20 and its 200 day simple moving average is $38.82.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.